IDEC is a leader in the discovery, development, and commercialization of targeted immunotherapies for the treatment of cancer and autoimmune diseases. IDEC discovered and developed the first commercially available radioimmunotherapy product (Zevalin) approved in the United States, which is used to treat certain non-Hodgkin's lymphomas. IDEC also discovered and, with co-promotion partner Genentech, Inc., developed the first monoclonal antibody product (Rituxan) approved in the United States for the treatment of cancer. Rituxan is approved in over 70 countries worldwide and is also used to treat various types of non-Hodgkin's lymphomas. IDEC is a San Diego-based, integrated biopharmaceutical company with multiple products in clinical stage development and strategic alliances in a variety of research platforms.
View Top Employees from IDEC Pharmaceuticals Corporation| Website | http://www.idecpharm.com |
| Employees | View employees |
| Founded | 1985 |
| Address | 3030 Callan Rd, San Diego, California 92121, US |
| Phone | (858) 431-8500 |
| Industry | Manufacturing General, Biotechnology, Manufacturing, Drug Discovery |
| Competitors | Autoimmune Inc, Patrys Limited, ProlX Pharmaceuticals Corp, XTL Biopharmaceuticals Ltd. |
| SIC | SIC Code 2834 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
| NAICS | NAICS Code 32541 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular IDEC Pharmaceuticals Corporation employee's phone or email?
IDEC Pharmaceuticals Corporation Questions
IDEC Pharmaceuticals Corporation is based in San Diego, California.
The NAICS codes for IDEC Pharmaceuticals Corporation are [32541, 325, 32, 3254].
The SIC codes for IDEC Pharmaceuticals Corporation are [2834, 283, 28].
